Shareholders in Editas Medicine (NASDAQ:EDIT) have lost 83%, as stock drops 9.4% this past week

Simply Wall St.04-06

As an investor, mistakes are inevitable. But really bad investments should be rare. So consider, for a moment, the misfortune of Editas Medicine, Inc. (NASDAQ:EDIT) investors who have held the stock...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2425502745?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2024-04-06 20:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2425502745","market":"sg","top_or_hot":-1,"title":"Shareholders in Editas Medicine (NASDAQ:EDIT) have lost 83%, as stock drops 9.4% this past week","media":"Simply Wall St.","content":"<div>\n<p>As an investor, mistakes are inevitable.  But really bad investments should be rare.  So consider, for a moment, the misfortune of Editas Medicine, Inc. (NASDAQ:EDIT) investors who have held the stock...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-edit/editas-medicine/news/shareholders-in-editas-medicine-nasdaqedit-have-lost-83-as-s\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shareholders in Editas Medicine (NASDAQ:EDIT) have lost 83%, as stock drops 9.4% this past week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShareholders in Editas Medicine (NASDAQ:EDIT) have lost 83%, as stock drops 9.4% this past week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-06 20:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-edit/editas-medicine/news/shareholders-in-editas-medicine-nasdaqedit-have-lost-83-as-s><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As an investor, mistakes are inevitable.  But really bad investments should be rare.  So consider, for a moment, the misfortune of Editas Medicine, Inc. (NASDAQ:EDIT) investors who have held the stock...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-edit/editas-medicine/news/shareholders-in-editas-medicine-nasdaqedit-have-lost-83-as-s\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FT_SY_MNQ","symbol_name":"微型NQ100指数","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-edit/editas-medicine/news/shareholders-in-editas-medicine-nasdaqedit-have-lost-83-as-s","article_id":"2425502745","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2425502745","pubTimestamp":1712405975,"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"As an investor, mistakes are inevitable. But really bad investments should be rare. So consider, for a moment, the...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"SQQQ":"纳指三倍做空ETF","BK4112":"金融交易所和数据","QID":"纳指两倍做空ETF","BK4139":"生物科技","EDIT":"Editas Medicine, Inc.","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","PSQ":"纳指反向ETF","QLD":"纳指两倍做多ETF","QQQ":"纳指100ETF","BK4585":"ETF&股票定投概念","BK4588":"碎股","TQQQ":"纳指三倍做多ETF","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD",".IXIC":"NASDAQ Composite","NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4556":"基因编辑"},"translate_title":"Editas Medicine（纳斯达克：EDIT）的股东损失了83%，股票在过去一周下跌了9.4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EDIT":1,"NDAQ":1,".IXIC":1,"TQQQ":0.6,"SQQQ":0.6,"QQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"NQmain":0.6,"MNQmain":0.6},"content_text":"As an investor, mistakes are inevitable.  But really bad investments should be rare.  So consider, for a moment, the misfortune of Editas Medicine, Inc. (NASDAQ:EDIT) investors who have held the stock for three years as it declined a whopping 83%.  That would certainly shake our confidence in the decision to own the stock.     The falls have accelerated recently, with the share price down 26% in the last three months.       While a drop like that is definitely a body blow, money isn't as important as health and happiness.   If the past week is anything to go by, investor sentiment for Editas Medicine isn't positive, so let's see if there's a mismatch between fundamentals and the share price.   See our latest analysis for Editas Medicine   Editas Medicine isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing.  Shareholders of unprofitable companies usually desire strong revenue growth.  That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.   In the last three years Editas Medicine saw its revenue shrink by 34% per year.   That means its revenue trend is very weak compared to other loss making companies.   And as you might expect the share price has been weak too, dropping at a rate of 22% per year.  We prefer leave it to clowns to try to catch falling knives, like this stock.  There is a good reason that investors often describe buying a sharply falling stock price as 'trying to catch a falling knife'. Think about it.       The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail). NasdaqGS:EDIT Earnings and Revenue Growth April 6th 2024 Editas Medicine is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth.  If you are thinking of buying or selling Editas Medicine stock, you should check out this free report showing analyst consensus estimates for future profits.  A Different Perspective Editas Medicine shareholders are down 2.9% for the year, but the market itself is up 28%.  Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested.    Unfortunately, longer term shareholders are suffering worse, given the loss of 12% doled out over the last five years.  We would want clear information suggesting the company will grow, before taking the view that the share price will stabilize.       It's always interesting to track share price performance over the longer term. But to understand Editas Medicine better, we need to consider many other factors.   Consider for instance, the ever-present spectre of investment risk.   We've identified 4 warning signs  with Editas Medicine , and understanding them should be part of your investment process.    If you are like me, then you will not want to miss this free list of growing companies that insiders are buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.Valuation is complex, but we're helping make it simple.Find out whether Editas Medicine is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2425502745"}